Loading

Please wait...

Xeljanz xr

Generic Name: tofacitinib (TOE fa SYE ti nib)
Brand Names: Xeljanz, Xeljanz XR
Xeljanz (tofacitinib) is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Includes Xeljanz side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Xeljanz xr

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Xeljanz (tofacitinib) blocks the activity of certain enzymes in the body that affect immune system function. Xeljanz is used to treat moderate to severe rheumatoid arthritis or active psoriatic arthritis in adults who have tried Methotrexate or other medications without successful treatment of symptoms. Tofacitinib is sometimes given in combination with Methotrexate or other arthritis medicines. Xeljanz is also used to treat adults with moderate to severe ulcerative colitis in adults who cannot use certain other medications, or after other treatments have failed. Learn more

Xeljanz xr Side Effects

Xeljanz Side Effects

Note: This document contains side effect information about tofacitinib. Some of the dosage forms listed on this page may not apply to the brand name Xeljanz.

In Summary

Common side effects of Xeljanz include: infection. Other side effects include: diarrhea and headache. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to tofacitinib: oral tablet, oral tablet extended release

Warning

Oral route (Tablet; Tablet, Extended Release)

Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving tofacitinib. If a serious infection develops, interrupt tofacitinib until the infection is controlled. Prior to starting tofacitinib and during therapy, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting tofacitinib. Monitor all patients for the development of signs and symptoms of infection during and after treatment with tofacitinib, including active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with tofacitinib. Epstein Barr virus-associated posttransplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with tofacitinib and concomitant immunosuppressive medications.

Along with its needed effects, tofacitinib (the active ingredient contained in Xeljanz) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tofacitinib:

Less common

  • Bladder pain
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • chills
  • cough
  • difficult, burning, or painful urination
  • difficulty breathing
  • dizziness
  • ear congestion
  • fever
  • frequent urge to urinate
  • headache
  • loss of voice
  • lower back or side pain
  • muscle aches
  • nervousness
  • pounding in the ears
  • slow or fast heartbeat
  • sneezing
  • sore throat
  • stuffy or runny nose
  • unusual tiredness or weakness

Incidence not known

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • confusion
  • dark urine
  • decreased urination
  • difficult or labored breathing
  • dry mouth
  • fainting
  • increase in heart rate
  • light-colored stools
  • lightheadedness
  • nausea
  • pale skin
  • persistent non-healing sore
  • rapid breathing
  • rapid weight gain
  • reddish patch or irritated area
  • sunken eyes
  • thirst
  • tightness in the chest
  • tingling of the hands or feet
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual weight gain or loss
  • upper right abdominal or stomach pain
  • vomiting
  • wrinkled skin
  • yellow eyes and skin

Some side effects of tofacitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Diarrhea

Incidence not known

  • Belching
  • burning feeling in the chest or stomach
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • difficulty with moving
  • flushing or redness of the skin
  • heartburn
  • indigestion
  • itching skin, rash
  • muscle pain or stiffness
  • pain in the joints
  • stomach discomfort, upset, or pain
  • tenderness in the stomach area
  • trouble sleeping
  • unusually warm skin

For Healthcare Professionals

Applies to tofacitinib: oral tablet, oral tablet extended release

General

The most common serious adverse reactions were serious infections.

Cardiovascular

Common (1% to 10%): Hypertension

Dermatologic

Frequency not reported: Rash, erythema, pruritus

Gastrointestinal

Common (1% to 10%): Diarrhea, abdominal pain, dyspepsia, vomiting, gastritis, nausea, vomiting, constipation, gastritis, gastroenteritis

Hematologic

Frequency not reported: Anemia, neutropenia, lymphopenia

Hepatic

Common (1% to 10%): AST elevation, ALT elevation

Frequency not reported: Hepatic steatosis, elevated bilirubin

Immunologic

Very common (10% or more): Overall infections (up to 22%)

Frequency not reported: Serious infection (most commonly pneumonia, cellulitis, herpes zoster and urinary tract infection), other non-TB opportunistic infection

Metabolic

Frequency not reported: Dehydration, increased total cholesterol, increased LDL cholesterol, increased HDL cholesterol, increased triglycerides

Musculoskeletal

Common (1% to 10%): Rheumatoid arthritis, back pain, arthralgia

Frequency not reported: Musculoskeletal pain, tendonitis, joint swelling

Nervous system

Common (1% to 10%): Headache, dizziness

Frequency not reported: Paresthesia

Oncologic

Frequency not reported: Lung cancer, breast cancer, gastric cancer, colorectal cancer, renal cell cancer, prostate cancer, lymphoma, malignant melanoma, non-melanoma skin cancer

Other

Frequency not reported: Pyrexia, fatigue, peripheral edema

Psychiatric

Frequency not reported: Insomnia

Renal

Common (1% to 10%): Increased serum creatinine

Respiratory

Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, bronchitis, cough

Frequency not reported: Dyspnea, sinus congestion, tuberculosis (TB)

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Xeljanz Xr (www.drugs.com/xeljanz.html).